Q-omics provides the consensus-scored TRGV6 profile across patient tissues and cancer cell-line models. TRGV6 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRGV6 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, TRGV6 RNA expression shows 13,435 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, LUAD, and DLBC as cancer lineages where TRGV6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRGV6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRGV6 survival associations across molecular data types. TRGV6 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRGV6 RNA expression–survival associations across cancer types. High TRGV6 expression shows unfavorable associations in ACC, UVM, GBM, LUSC and UCS, but favorable associations in MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRGV6 RNA expression.
This table summarizes TRGV6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRGV6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRGV6 shows lower tumor expression in LUAD, LUSC, COAD and UCEC and higher tumor expression in KIRC and HNSC. The LUAD box plot shows higher TRGV6 RNA expression in normal versus tumor tissue (log2 FC = −1.029, t-test p < 0.001).
This table shows molecular features associated with TRGV6 in patient tissues and cancer cell lines. In patient samples, TRGV6 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
